FindTrial
Sign In

Study on the relationship between HER2 mutation, amplification and expression levels and drug sensitivity of trastuzumab deruxtecan in pancancerous solid tumors

Study on the relationship between HER2 mutation, amplification and expression levels and drug sensitivity of trastuzumab deruxtecan in pancancerous solid tumors

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037085
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, gastric and colorectal cancer, and non-small lumg cancer

Interventions

experimental group:DS8201a
control group:DMSO

Sponsors

Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Abnormal HER2 status

Exclusion criteria

Exclusion criteria: None tumor tissue

Design outcomes

Primary

MeasureTime frame
HER2;—

Countries

China

Contacts

Public ContactAnqi Li

Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University

annlaq@163.com+86 18917800439

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026